Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155


Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling.

Lee A, Frischer J, Serur A, Huang J, Bae JO, Kornfield ZN, Eljuga L, Shawber CJ, Feirt N, Mansukhani M, Stempak D, Baruchel S, Glade Bender J, Kandel JJ, Yamashiro DJ.

Cancer Res. 2006 Apr 15;66(8):4378-84.


Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis.

Huang J, Soffer SZ, Kim ES, McCrudden KW, Huang J, New T, Manley CA, Middlesworth W, O'Toole K, Yamashiro DJ, Kandel JJ.

Mol Cancer Res. 2004 Jan;2(1):36-42.


Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.

Tuccillo C, Romano M, Troiani T, Martinelli E, Morgillo F, De Vita F, Bianco R, Fontanini G, Bianco RA, Tortora G, Ciardiello F.

Clin Cancer Res. 2005 Feb 1;11(3):1268-76.


Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.

Frischer JS, Huang J, Serur A, Kadenhe-Chiweshe A, McCrudden KW, O'Toole K, Holash J, Yancopoulos GD, Yamashiro DJ, Kandel JJ.

Int J Oncol. 2004 Sep;25(3):549-53.


Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.

Roberts WG, Whalen PM, Soderstrom E, Moraski G, Lyssikatos JP, Wang HF, Cooper B, Baker DA, Savage D, Dalvie D, Atherton JA, Ralston S, Szewc R, Kath JC, Lin J, Soderstrom C, Tkalcevic G, Cohen BD, Pollack V, Barth W, Hungerford W, Ung E.

Cancer Res. 2005 Feb 1;65(3):957-66.


Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.

Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, Herbst RS, O'Reilly MS.

Mol Cancer Ther. 2007 Feb;6(2):471-83.


Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1alpha/CXCR4 axis.

Song N, Huang Y, Shi H, Yuan S, Ding Y, Song X, Fu Y, Luo Y.

Cancer Res. 2009 Aug 1;69(15):6057-64. doi: 10.1158/0008-5472.CAN-08-2007.


rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice.

Davidoff AM, Nathwani AC, Spurbeck WW, Ng CY, Zhou J, Vanin EF.

Cancer Res. 2002 Jun 1;62(11):3077-83.


The role of platelet-derived growth factor signaling in healing myocardial infarcts.

Zymek P, Bujak M, Chatila K, Cieslak A, Thakker G, Entman ML, Frangogiannis NG.

J Am Coll Cardiol. 2006 Dec 5;48(11):2315-23.


VEGF-C regulates lymphangiogenesis and capillary stability by regulation of PDGF-B.

Onimaru M, Yonemitsu Y, Fujii T, Tanii M, Nakano T, Nakagawa K, Kohno R, Hasegawa M, Nishikawa S, Sueishi K.

Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1685-96. doi: 10.1152/ajpheart.00015.2009.


Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.

Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.

Clin Cancer Res. 2008 Apr 1;14(7):2210-9. doi: 10.1158/1078-0432.CCR-07-1893.


Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis.

Zhao QT, Yue SQ, Cui Z, Wang Q, Cui X, Zhai HH, Zhang LH, Dou KF.

Life Sci. 2007 Jan 9;80(5):484-92.


Cyclooxygenase-2 in cancer cells and macrophages induces colon cancer cell growth by cigarette smoke extract.

Liu ES, Shin VY, Ye YN, Luo JC, Wu WK, Cho CH.

Eur J Pharmacol. 2005 Jul 25;518(1):47-55.


KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.

Nakamura K, Taguchi E, Miura T, Yamamoto A, Takahashi K, Bichat F, Guilbaud N, Hasegawa K, Kubo K, Fujiwara Y, Suzuki R, Kubo K, Shibuya M, Isae T.

Cancer Res. 2006 Sep 15;66(18):9134-42.


In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models.

Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, Nordahl L, Garrett E, Samara E, Aukerman SL, Gelb AB, Heise C.

Clin Cancer Res. 2005 May 15;11(10):3633-41.


Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner.

Guleng B, Tateishi K, Ohta M, Kanai F, Jazag A, Ijichi H, Tanaka Y, Washida M, Morikane K, Fukushima Y, Yamori T, Tsuruo T, Kawabe T, Miyagishi M, Taira K, Sata M, Omata M.

Cancer Res. 2005 Jul 1;65(13):5864-71.


A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells.

Basu GD, Liang WS, Stephan DA, Wegener LT, Conley CR, Pockaj BA, Mukherjee P.

Breast Cancer Res. 2006;8(6):R69.


Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.

Coxon A, Bush T, Saffran D, Kaufman S, Belmontes B, Rex K, Hughes P, Caenepeel S, Rottman JB, Tasker A, Patel V, Kendall R, Radinsky R, Polverino A.

Clin Cancer Res. 2009 Jan 1;15(1):110-8. doi: 10.1158/1078-0432.CCR-08-1155.

Items per page

Supplemental Content

Support Center